Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals    ALXN

ALEXION PHARMACEUTICALS (ALXN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Alexion Pharmaceuticals : Agrees to Work With Hedge Fund Elliott on Filling Board Seat--Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/03/2018 | 01:08am CEST
By Aisha Al-Muslim 

Alexion Pharmaceuticals Inc. said Tuesday it will work with hedge fund Elliott Management Corp. on filling an open board seat.

The move comes as the rare-disease drugmaker has been facing pressure from the activist investor, which has pushed for changes in recent years at companies including aluminum parts maker Arconic Inc. and Brocade Communication Systems, now part of Broadcom Ltd.

The agreement between the board and Elliott is part of efforts to "maintain active and constructive dialogue with all of our shareholders, " Alexion Board Chairman David Brennan said in prepared remarks.

The New York Times reported last month, citing two unnamed sources, that Elliott had built a stake in Alexion and urged the company to make changes to lift its stock price.

Alexion said in November that it was searching for a candidate to fill a seat on its board, which currently has 11 members.

The company and Elliott declined to comment Tuesday on the size of Elliott's stake in the firm.

The New Haven, Conn., drugmaker, founded in 1992, has had many management changes during the past year, including hiring Chief Executive Ludwig Hantson in March, after an internal investigation showed senior management pressured staff to persuade customers to order its flagship drug earlier than needed to meet financial targets.

The company's primary product is a rare blood-disease treatment named Soliris.

Under Mr. Hantson's leadership, much of the senior management team was replaced. Alexion in September said it was cutting its workforce by 20%, relocating its headquarters to Boston and closing sites as it works to reduce its overhead. The moves were expected to create $250 million in annual cost savings by 2019.

"We are encouraged by actions taken under Ludwig's leadership to improve financial performance and reset Alexion's strategy," an Elliott spokesperson said in prepared remarks.

Shares in Alexion, down nearly 12% in the past three months, were unchanged at $124.05 in after-hours trading Tuesday. Alexion had a stock market value of $27.71 billion as of market close.

Write to Aisha Al-Muslim at aisha.al-muslim@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALEXION PHARMACEUTICALS
10/10ALEXION PHARMACEUTICALS : to Report Third Quarter 2018 Results on Wednesday, Oct..
AQ
10/04ALEXION PHARMACEUTICALS : to Report Third Quarter 2018 Results on Wednesday, Oct..
BU
10/01ALEXION PHARMACEUTICALS : to Acquire Syntimmune
AQ
10/01ALEXION PHARMACEUTICALS : to Present at the Leerink Partners Roundtable Series, ..
AQ
10/01Blueprint Medicines unveils preclinical data for rare bone disease program
AQ
09/27ALEXION PHARMACEUTICALS : Correction to Alexion to Buy Syntimmune Stories on Sep..
DJ
09/26ALEXION PHARMACEUTICALS : Announces Successful Phase 3 PREVENT Study of Soliris ..
AQ
09/26ALEXION PHARMACEUTICALS : to Buy Syntimmune for Up to $1.2 Billion -- Update
DJ
09/26MARKETS RIGHT NOW : Stocks open higher on Wall Street
AQ
09/26ALEXION PHARMACEUTICALS : to Acquire Syntimmune
BU
More news
News from SeekingAlpha
10/18MARKER THERAPEUTICS : A Safer And Potentially More Effective CAR-T Alternative 
10/09Invesco S&P 500 Equal Weight ETF (RSP) September Summary 
10/05The Biotech Conundrum 
10/03Healthcare And Biotechnology Dashboard - Update 
09/27Best And Worst-Performing Stocks In The S&P 500 Over The Last 20 Years And Ho.. 
Financials ($)
Sales 2018 4 041 M
EBIT 2018 2 021 M
Net income 2018 189 M
Debt 2018 1 532 M
Yield 2018 -
P/E ratio 2018 66,08
P/E ratio 2019 20,58
EV / Sales 2018 7,32x
EV / Sales 2019 5,44x
Capitalization 28 056 M
Chart ALEXION PHARMACEUTICALS
Duration : Period :
Alexion Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALEXION PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 163 $
Spread / Average Target 30%
EPS Revisions
Managers
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
David Richard Brennan Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
John J. Orloff Executive VP & Head-Research & Development
Andreas Rummelt Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS1.59%28 205
BIOGEN3.09%66 506
CSL LIMITED33.70%60 790
BIOMARIN PHARMACEUTICAL11.60%18 437
GRIFOLS-9.36%16 648
WUXI BIOLOGICS CAYMAN INC--.--%9 830